Related references
Note: Only part of the references are listed.Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.
Van K. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Jun Tian et al.
NATURE MEDICINE (2023)
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Rona Yaeger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
Javier Ros et al.
FRONTIERS IN ONCOLOGY (2023)
BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
David S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
ANCHOR CRC: Results From a Single-Arm , Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
John H Strickler et al.
LANCET ONCOLOGY (2023)
Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond
Samar Al Bitar et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2023)
Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy A Phase 1 Nonrandomized Clinical Trial
Marwan Fakih et al.
JAMA ONCOLOGY (2023)
Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: A phase 2 trial
Xianhua Fu et al.
CANCER SCIENCE (2023)
Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis
Fausto Petrelli et al.
DIGESTIVE AND LIVER DISEASE (2023)
Regorafenib plus nivolumab in patients with mismatch repair- proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
Marwan Fakih et al.
ECLINICALMEDICINE (2023)
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer
Valerie Boige et al.
JAMA NETWORK OPEN (2023)
Nivolumab (NIVO)+5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF(V600E) metastatic colorectal cancer
Van K. Morris et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC)
Afsaneh Barzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A phase II study of pembrolizumab, binimetinib, and bevacizumab in patients with microsatellitestable, refractory, metastatic colorectal cancer (mCRC)
Tyler Friedrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma
Ting Ye et al.
FRONTIERS IN IMMUNOLOGY (2022)
Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
Quang Loc Bui et al.
CANCERS (2022)
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer A Randomized Clinical Trial
Niharika B. Mettu et al.
JAMA NETWORK OPEN (2022)
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial
Federica Morano et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
Carlotta Antoniotti et al.
LANCET ONCOLOGY (2022)
Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study
Jinjia Chang et al.
CLINICAL COLORECTAL CANCER (2022)
Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
Joseph Tintelnot et al.
FRONTIERS IN ONCOLOGY (2022)
Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
Y. Kuboki et al.
ANNALS OF ONCOLOGY (2022)
Phase II study of durvalumab anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Benny Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer
J. Tabernero et al.
ESMO OPEN (2022)
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study
Ranju Gupta et al.
JCO PRECISION ONCOLOGY (2022)
Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status
Avraham Travers et al.
CLINICAL COLORECTAL CANCER (2021)
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
Sophie Cousin et al.
CLINICAL CANCER RESEARCH (2021)
The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer
Mehran Pashirzad et al.
CURRENT CANCER DRUG TARGETS (2021)
KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
Joshua K. Sabari et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer
Manish R. Patel et al.
CANCER MEDICINE (2021)
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena et al.
LANCET ONCOLOGY (2021)
Durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS-mutated metastatic colorectal cancer: First results of efficacy at one year for phase II MEDITREME trial
J-D. Fumet et al.
ANNALS OF ONCOLOGY (2021)
The current understanding on the impact of KRAS on colorectal cancer
Mingjing Meng et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
Ho Wai Derrick Siu et al.
BMC CANCER (2021)
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies
Lisa Salvatore et al.
CANCER TREATMENT REVIEWS (2021)
Targeting Son of Sevenless 1: The pacemaker of KRAS
Dirk Kessler et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2021)
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial
Erika Martinelli et al.
JAMA ONCOLOGY (2021)
Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial
Benjamin Besse et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Updated results from a phase Ib trial of regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer (REGONIVO, EPOC1603).
Kohei Shitara et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).
Caio Max Sao Pedro Rocha Lima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients
Changwen Jing et al.
MOLECULAR CARCINOGENESIS (2020)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
Marta Schirripa et al.
CLINICAL COLORECTAL CANCER (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer
Patricia Martin-Romano et al.
EUROPEAN JOURNAL OF CANCER (2020)
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colrectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi et al.
ESMO OPEN (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
Albert Tuca et al.
JOURNAL OF CLINICAL MEDICINE (2020)
PEMBROLIZUMAB IN COMBINATION WITH XELOX BEVACIZUMAB IN PATIENTS WITH MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE: A PROOF OF CONCEPT STUDY. FFCD 1703 POCHI
David Tougeron et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.
Salvatore Siena et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
Filippo Pietrantonio et al.
JAMA ONCOLOGY (2019)
ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials
Omar Abdel-Rahman
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2019)
Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)
David Hyman et al.
CANCER RESEARCH (2019)
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
Francesca Battaglin et al.
BMC CANCER (2018)
The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review
Nele Boeckx et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
E. Aranda et al.
EUROPEAN JOURNAL OF CANCER (2018)
Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Sandrine Aspeslagh et al.
EUROPEAN JOURNAL OF CANCER (2017)
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
Sebastian Stintzing et al.
EUROPEAN JOURNAL OF CANCER (2017)
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers
Mohamed E. Salem et al.
ONCOTARGET (2017)
Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study
K. K. H. Goey et al.
ANNALS OF ONCOLOGY (2017)
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
S. Y. Brule et al.
EUROPEAN JOURNAL OF CANCER (2015)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch et al.
CLINICAL CANCER RESEARCH (2014)
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
J. C. von Einem et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Chengwen Liu et al.
CLINICAL CANCER RESEARCH (2013)
Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study
Luca Moscetti et al.
INVESTIGATIONAL NEW DRUGS (2013)
Bevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase Ill 'Stop and Go' Study Results - A Turkish Oncology Group Trial
Suayib Yalcin et al.
ONCOLOGY (2013)
Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients
Cirino Botta et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C. Bokemeyer et al.
ANNALS OF ONCOLOGY (2011)
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation
Jeanne Tie et al.
INTERNATIONAL JOURNAL OF CANCER (2011)